Single-Photon Emission Computed Tomography with 99mTc-1-Thio-D-glucose in Evaluation of the Effectiveness and Prediction of the Results of Treatment of Lymphoproliferative Diseases
- Authors: Chernov V.I.1,2, Dudnikova E.A.1, Zelchan R.V.1,2, Bragina O.D.1,2, Medvedeva A.A.1, Rybina A.N.1, Muravleva A.V.1, Kravchuk T.L.1, Goldberg V.E.1
-
Affiliations:
- Cancer Research Institute, Tomsk National Research Medical Center
- Research Centrum for Oncotheranostics, Tomsk Polytechnic University
- Issue: Vol 68, No 1 (2023)
- Pages: 86-91
- Section: Nuclear Medicine
- URL: https://bakhtiniada.ru/1024-6177/article/view/363814
- DOI: https://doi.org/10.33266/1024-6177-2023-68-1-86-91
- ID: 363814
Cite item
Full Text
Abstract
Purpose: Study of 99mTc-1-thio-D-glucose (99mTc-TG) SPECT using fore possibility to assess the effectiveness of therapy and predict the results of lymphomas treatment.
Material and methods: We analyzed 99mTc-TG SPECT data of 30 people with malignant lymphomas: before treatment (SPECT1), after two courses (SPECT2) and after completion of chemotherapy (SPECT3).
Results: By the results of SPECT2 analyzing, a complete metabolic response after two courses of chemotherapy (SPECT2–) was observed in 15 patients (50 %). In 15 patients, after 2 cycles of chemotherapy, a partial metabolic response (12 people) or no metabolic response (3 people) was established. These patients constituted the SPECT2+ group.
After completion of chemotherapy, a complete metabolic response (SPECT3–) was diagnosed in 21 (70 %) patients. This effect was obtained in 15 (100 %) patients with SPECT2– and in 6 patients (40 %) with SPECT2+. Of the 15 patients in the SPECT2+ group, 9 (60 %) patients after completion of chemotherapy were diagnosed with a partial metabolic response (6 people) or metabolic progression (3 people).
By two-year follow-up of patients, show that remission was observed in 23 (77 %) patients (complete remission in 15 people, uncertain complete remission in 8 patients). The relapse group consisted of 7 (23 %) cases, while 4 patients had a relapse of the disease, and 3 had progression. In SPECT2+ group, relapse of the disease was observed in 6 (40 %) cases, and remission in 9 (60 %) patients. While in SPECT2– group 1 (7 %) person relapse was diagnosed and 14 (93 %) were in remission (p<0.05).
Conclusion: 99mTc-TG SPECT makes it possible to evaluate the results of lymphomas treatment with high efficiency. The presence of a complete metabolic response of the tumor after two courses of therapy indicates a high level of disease-free survival.
About the authors
V. I. Chernov
Cancer Research Institute, Tomsk National Research Medical Center; Research Centrum for Oncotheranostics, Tomsk Polytechnic University
Email: chernov@tnimc.ru
Tomsk, Russia
E. A. Dudnikova
Cancer Research Institute, Tomsk National Research Medical Center
Email: chernov@tnimc.ru
Tomsk, Russia
R. V. Zelchan
Cancer Research Institute, Tomsk National Research Medical Center; Research Centrum for Oncotheranostics, Tomsk Polytechnic University
Email: chernov@tnimc.ru
Tomsk, Russia
O. D. Bragina
Cancer Research Institute, Tomsk National Research Medical Center; Research Centrum for Oncotheranostics, Tomsk Polytechnic University
Email: chernov@tnimc.ru
Tomsk, Russia
A. A. Medvedeva
Cancer Research Institute, Tomsk National Research Medical Center
Email: chernov@tnimc.ru
Tomsk, Russia
A. N. Rybina
Cancer Research Institute, Tomsk National Research Medical Center
Email: chernov@tnimc.ru
Tomsk, Russia
A. V. Muravleva
Cancer Research Institute, Tomsk National Research Medical Center
Email: chernov@tnimc.ru
Tomsk, Russia
T. L. Kravchuk
Cancer Research Institute, Tomsk National Research Medical Center
Email: chernov@tnimc.ru
Tomsk, Russia
V. E. Goldberg
Cancer Research Institute, Tomsk National Research Medical Center
Email: chernov@tnimc.ru
Tomsk, Russia
References
- Poddubnaya I.V., Savchenko V.G. Rossiyskiye Klinicheskiye Rekomendatsii po Diagnostike i Lecheniyu Zlokachestvennykh Limfoproliferativnykh Zabolevaniy = Recommendations for the Diagnosis and Treatment of Malignant Lymphoproliferative Diseases. Мoscow Publ., 2018. 470 c. (In Russ.).
- Barrington S.F., Mikhaeel N.G., Kostakoglu L., et al. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J. Clin. Oncol. 2014;32:3048–3058. doi: 10.1200/JCO.2013.53.5229.
- Dreyling M., Thieblemont C., Gallamini A. et al. ESMO Consensus Conferences: Guidelines on Malignant Lymphoma. Part 2: Marginal Zone Lymphoma, Mantle Cell Lymphoma, Peripheral T-Cell Lymphoma. Ann Oncol. 2013;24:857–877. doi: 10.1093/annonc/mds643.
- Radford J., Illidge T., Counsell N. et al. Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma. New England Journal of Medicine. 2015;372;17:1598–1607. doi: 10.1056/NEJMoa1408648.
- Chanchikova N.G., Chernov V.I., Dudnikova Ye.A., et al. The Role of 18F-FDG PET/CT in Evaluation of Therapy Effectiveness and Prognosis of Lymphomas. Byulleten Sibirskoy Meditsiny = Bulletin of Siberian Medicine. 2021;20;2:120–129. DOI: org/10.20538/1682-0363-2021-2-120-129 (In Russ.).
- Chernov V.I., Dudnikova Ye.A., Goldberg V.Ye., et al. Positron Emission Tomography in the Diagnosis and Monitoring of Lymphomas. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost = Medical Radiology and Radiation Safety. 2018;63;6:41–50. doi: 10.12737/article_5c0b8d72a8bb98.40545646 (In Russ.).
- Chanchikova N.G., Dudnikova Ye.A., Karlova Ye.A., et al. Possibilities of 18F-FDG PET/CT in the diagnosis and staging of lymphomas. Voprosy Onkologii = Problems in Oncology. 2019;65;1:147–153. DOI: org/10.37469/0507-3758-2019-65-1-147-153 (In Russ.).
- Chernov V.I., Dudnikova Ye.A., Goldberg V.Ye., et al. Single-Photon Emission Computerized Tomography in the Diagnosis and Monitoring of Lymphomas. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost = Medical Radiology and Radiation Safety. 2019;64;3:58–63. doi: 10.12737/article_5cf3dfefe60b13.90120976 (In Russ.).
- Zeltchan R., Medvedeva A., Sinilkin I., et al. Experimental Study of Radiopharmaceuticals Based on Technetium-99m Labeled Derivative of Glucose for Tumor Diagnosis. IOP Conference Series. Materials Science and Engineering. 2016. doi: 10.1088/1757-899X/135/1/012054.
- Zelchan R.V., Medvedeva A.A., Sinilkin I.G., et al. Study of Functional Suitability Tumor Tropism Radiopharmaceuticals99mTc-1-Thio-D-Glucose in the Experiment. Molekulyarnaya Meditsina = Molecular Medicine. 2018;16;2:54–57. DOI: https://doi.org/10.29296/24999490-2018-03-11 (In Russ.).
- Chernov V.I., Medvedeva A.A., Sinilkin I.G., et al. Development Radiopharmaceuticals for Nuclear Medicine in Oncology. Meditsinskaya Vizualizatsiya = Medical Visualization. 2016;2:63–66 (In Russ.).
- Chernov V.I., Dudnikova Ye.A., Zelchan R.V., et al. The First Experience of Using 99mTc-1-Thio-d-Glucose for Single-Photon Emission Computed Tomography Imaging of Lymphomas. Sibirskiy Onkologicheskiy Zhurnal = Siberian Journal of Oncology. 2018;17;4:81–87. doi: 10.21294/1814-4861-2018-17-4-81-87 (In Russ.).
- Dudnikova Ye.A., Chernov V.I., Muravleva A.V., et al. Metabolic Single-Photon Emission Computed Tomography with the New Radiopharmaceutical 99mTc-1-Thio-D-Glucose in the Diagnosis and Monitoring of the Primary Breast Lymphoma (Case Report). Sibirskiy Onkologicheskiy Zhurnal = Siberian Journal of Oncology. 2020;19;5:145–153. doi: 10.21294/1814-4861-2020-19-5-145-153 (In Russ.).
- Muravleva A.V., Chernov V.I., Dudnikova Ye.A., et al. Metabolic single-Photon Emission Computed Tomography with «99mTc-1-Thio-D-Glucose» - New Possibilities for Hodgkin’s Lymphoma Staging. Rossiyskiy Elektronnyy Zhurnal Luchevoy Diagnostiki = Russian Electronic Journal of Radiology. 2021;11;3:171–177. doi: 10.21569/2222-7415-2021-11-3-171-177 (In Russ.).
- Chernov V., Dudnikova E., Zelchan R., et al. Phase I Clinical Trial Using [99mTc]Tc-1-Thio-D-Glucose for Diagnosis of Lymphoma Patients. Pharmaceutics. 2022;14:1274. https://doi.org/10.3390/pharmaceutics14061274.
Supplementary files
